Bio-Path Holdings Information

Bio-Path is a publicly traded biotechnology company focused on developing therapeutic products utilizing its proprietary DNAbilize™ technology designed to distribute nucleic acid drugs throughout the human body with a simple intravenous infusion. The Company’s initial focus is in oncology. Bio-Path’s lead product candidate, prexigebersen, (BP1001), is in Phase II clinical trials for AML in combination with LDAC in elderly de novo patients. The safety segment of the Phase II trial for prexigebersen + dasatinib in blast-phase and accelerated phase CML patients is expected to begin in 2017. Bio-Path’s second drug candidate, BP1002, is ready for the clinic where it will be evaluated in lymphoma and solid tumors. The technology behind prexigebersen is called DNAbilize™ Technology. DNAbilize is a liposomal antisense DNA platform with two critical improvements in oligonucleotide therapeutics. The main benefits to the patient are, 1: we have never had a single patient experience thrombocytopenia. Our drugs never damage platelets, and we are treating leukemia patients where thrombocytopenia is part of the disease. And 2: we have no liver toxicity; no elevation of transaminases. This makes the DNAbilize platform successful for treating systemic disease, such as blood cancers, as well as solid tumors, with no SAEs. Our platform is the most successful and safest DNA-based technology in clinical trials for hematological disease to date. We are interested in collaborations to develop therapeutics using DNAbilize™. Contact us at partnering@biopathholdings.com to discuss your drug development project.